Results 111 to 120 of about 21,018 (198)

Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia [PDF]

, 2019
Gilles Salles, Emmanuel Bachy, Lukáš Smolej, Martin Šimkovič, Lucile Baseggio, Anna Panovská, Hervé Besson, Nollaig Healy, Jamie Garside, Wafae Iraqi, Joris Diels, Corinna Pick-Lauer, Martin Špaček, Renata Urbanová, Daniel Lysák, Ruben Hermans, Jessica Lundbom, Evelyne Callet‐Bauchu, Michael Doubek   +18 more
openalex   +1 more source

A case report of hemophagocytic lymphohistiocytosis occurring during ibrutinib chemotherapy with a literature review. [PDF]

Medicine (Baltimore)
Hou X, Wang M, Miao S, Guo Y.
europepmc   +1 more source

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma [PDF]

, 2018
Alessandro Broccoli, Beatrice Casadei, Alice Morigi, Federico Sottotetti, Manuel Gotti, Michele Spina, Stefano Volpetti, Simone Ferrero, Francesco Spina, Francesco Pisani, Michele Merli, Carlo Visco, Rossella Paolini, Vittorio Ruggero Zilioli, Luca Baldini, Nicola Di Renzo, Patrizia Tosi, Nicola Cascavilla, Stefano Molica, Fiorella Ilariucci, Gian Matteo Rigolin, Francesco D’Alò, Anna Vanazzi, Elisa Santambrogio, Roberto Marasca, Lucia Mastrullo, Claudia Castellino, Giovanni Desabbata, Ilaria Scortechini, Livio Trentin, Lucia Morello, Lisa Argnani, Pier Luigi Zinzani   +32 more
openalex   +1 more source

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors. [PDF]

Front Pharmacol
Zhang Y, Fu H, Kang X, Qiu Z, Yan H, He Q, Yang B, Xu Z, Luo P.   +8 more
europepmc   +1 more source

Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes

, 2020
Joanna Rhodes, Vincent A. LoRe, Anthony R. Mato, Elise A. Chong, Jacqueline C. Barrientos, James N. Gerson, Stefan K. Barta, Daniel J. Landsburg, Sunita D. Nasta, Jakub Svoboda, Alison W. Loren, Stephen J. Schuster   +11 more
openalex   +2 more sources

Ibrutinib-Associated Liver Injury in a Patient with Chronic Lymphocytic Leukemia: Clinical Course and Therapeutic Approach. [PDF]

Hematol Rep
Frolli A, Parvis G, Bullo M, Grano S, Fornari G, Bonuomo V, Cilloni D, Fava C.   +7 more
europepmc   +1 more source

Immunoglobulin heavy-chain status and stromal interactions shape ferroptosis sensitivity in chronic lymphocytic leukemia. [PDF]

Signal Transduct Target Ther
Böttcher M, Reemts L, Hengeveld PJ, Böttcher-Loschinski R, Bhuria V, Lu J, Materna-Reichelt S, Das D, Stojanović Gužvić N, Bruns H, Huber W, Zenz T, Schanze D, Zenker M, Dietrich S, Langerak AW, Mougiakakos D.   +16 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter's syndrome. [PDF]

Leuk Res Rep
Meier T, Huynh G, Ayala E, Tun HW, Iqbal M.   +4 more
europepmc   +1 more source

Ibrutinib (Imbruvica)

CADTH
openalex   +2 more sources

Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN study. [PDF]

Blood Adv
García-Sanz R, Owen RG, Jurczak W, Dimopoulos MA, McCarthy H, Cull G, Opat SS, Castillo JJ, Kersten MJ, Wahlin BE, Grosicki S, Prathikanti R, Tian T, Allewelt H, Cohen AC, Tam CS.   +15 more
europepmc   +1 more source